Literature DB >> 29419344

Mitochondrial autophagosomes as a mechanism of drug resistance in breast carcinoma.

Ayman N Abunimer1, Heba Mohammed2, Katherine L Cook3, David R Soto-Pantoja3, Maria Mercedes Campos2, Mones S Abu-Asab2.   

Abstract

We have previously described the process by which mitochondria donate their membranes for the formation of autophagosomes, and in this study we show that the same process could be involved in drug sequestration and exocytosis resulting in multidrug-resistant cancerous cells. We examine the implications of mitochondrial vesicle formation of mitoautophagosomes (MAPS) in response to the cytotoxic drug MKT-077, which targets mortalin, in a drug-resistant breast carcinoma cell line overexpressing P-glycoprotein (P-gp). The breast cancer cell line MCF-7Adr is derived from MCF-7, but differs from its ancestral line in tolerance of MKT-077-induced mitochondrial toxicity. Our ultrastructural observations suggest that autophagy in the MCF-7Adr cells entails regional sequestration of MKT077 in multilamellar LC3-labeled MAPS, which then separate from their mitochondria, and fuse with or engulf each other. MAPS appeared to be migrating through the cytoplasm and fusing with the plasma membrane, thus carrying out exocytotic secretion. This mechanism, which seems ineffective in the ancestral cell line, provides a resistance mechanism for MKT-077 by enhancing the efflux process of the cells. After 8 hr of MKT-077 exposure, a fraction of the resistant cells appeared viable and contained larger number of smaller sized mitochondria. Mitoautophagosomes, therefore, provide a potentially novel model for multidrug resistance in cancerous cells and may contribute to the P-gp efflux process.

Entities:  

Keywords:  Breast carcinoma; MKT-077; P-glycoprotein; P-gp efflux pump; drug resistance; mitoautophagosomes; mitochondria; multidrug resistance

Mesh:

Substances:

Year:  2018        PMID: 29419344      PMCID: PMC6060621          DOI: 10.1080/01913123.2017.1419328

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  44 in total

1.  MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.

Authors:  N Brünner; B Boysen; S Jirus; T C Skaar; C Holst-Hansen; J Lippman; T Frandsen; M Spang-Thomsen; S A Fuqua; R Clarke
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

Review 2.  P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines.

Authors:  D Nielsen; T Skovsgaard
Journal:  Biochim Biophys Acta       Date:  1992-07-07

3.  Modes of internalizations of human prostate carcinoma (DU145) cells in vitro and in murine xenotransplants.

Authors:  Jacques Gilloteaux; Carston Ruffo; James M Jamison; Jack L Summers
Journal:  Ultrastruct Pathol       Date:  2016-05-10       Impact factor: 1.094

4.  Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.

Authors:  M R Abbaszadegan; A E Cress; B W Futscher; W T Bellamy; W S Dalton
Journal:  Cancer Res       Date:  1996-12-01       Impact factor: 12.701

5.  Activity of MKT 077, a rhodacyanine dye, against human tumor colony-forming units.

Authors:  T Petit; E Izbicka; R A Lawrence; C Nalin; S D Weitman; D D Von Hoff
Journal:  Anticancer Drugs       Date:  1999-03       Impact factor: 2.248

Review 6.  Multiple resistance to carcinogens and xenobiotics: P-glycoproteins as universal detoxifiers.

Authors:  Thomas Efferth; Manfred Volm
Journal:  Arch Toxicol       Date:  2017-02-07       Impact factor: 5.153

7.  Microparticle drug sequestration provides a parallel pathway in the acquisition of cancer drug resistance.

Authors:  Joyce Gong; Frederick Luk; Ritu Jaiswal; Anthony M George; Georges Emile Raymond Grau; Mary Bebawy
Journal:  Eur J Pharmacol       Date:  2013-10-03       Impact factor: 4.432

8.  Selective antitumor activity of MKT-077, a delocalized lipophilic cation, on normal cells and cancer cells in vitro.

Authors:  Y Chiba; T Kubota; M Watanabe; Y Otani; T Teramoto; Y Matsumoto; K Koya; M Kitajima
Journal:  J Surg Oncol       Date:  1998-10       Impact factor: 3.454

9.  MKT-077, a novel rhodacyanine dye in clinical trials, exhibits anticarcinoma activity in preclinical studies based on selective mitochondrial accumulation.

Authors:  K Koya; Y Li; H Wang; T Ukai; N Tatsuta; M Kawakami; L B Chen
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

10.  Selective damage to carcinoma mitochondria by the rhodacyanine MKT-077.

Authors:  J S Modica-Napolitano; K Koya; E Weisberg; B T Brunelli; Y Li; L B Chen
Journal:  Cancer Res       Date:  1996-02-01       Impact factor: 12.701

View more
  2 in total

1.  An Ultrastructural Perspective on Cell Death.

Authors:  Zaid R Najdawi; Mones S Abu-Asab
Journal:  Jordan Med J       Date:  2022-07-31

Review 2.  HSP70s in Breast Cancer: Promoters of Tumorigenesis and Potential Targets/Tools for Therapy.

Authors:  Alexander E Kabakov; Vladimir L Gabai
Journal:  Cells       Date:  2021-12-07       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.